Amicus Therapeutics (FOLD)

• Market cap: $1.86B
• 1 day: -2.27%
• 5 days: -2.58%
• 1 month: 0.17%
• 3 months: -31.56%
• 6 months: -35.58%
• Year to date: -35.23%
• 1 year: -43.38%
• 5 years: -45.87%
• 10 years: -56.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Employees: 499

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

31% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 86

25% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1.37% less ownership

Funds ownership: 102.09% [Q4 2024] → 100.72% (-1.37%) [Q1 2025]

1% less funds holding

Funds holding: 285 [Q4 2024] → 281 (-4) [Q1 2025]

12% less capital invested

Capital invested by funds: $2.87B [Q4 2024] → $2.53B (-$347M) [Q1 2025]

36% less call options, than puts

Call options by funds: $3.21M | Put options by funds: $5.05M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 49% upside
• Avg. target: $15.50 157% upside
• High target: $22 265% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

UBS Karl Chalabala	265% upside $22	Buy Maintained	2 May 2025
Goldman Sachs Salveen Richter	49% upside $9	Neutral Maintained	2 May 2025